Athersys Inc.

Company Overview

Athersys is a clinical-stage biopharmaceutical company with a growing pipeline of highly differentiated, potentially best-in-class therapeutics to treat significant and life-threatening diseases. It has established a pipeline of therapeutic product development programs in multiple disease areas; this pipeline includes both stem cell therapy and pharmaceuticals.

The company’s current product development portfolio consists of MultiStem, a proprietary non-embryonic stem cell product being developed as a treatment for multiple disease indications, which is currently being evaluated in several clinical trials. Areas of interest include evaluating the potential for MultiStem for the treatment of cardiovascular disease (e.g., treating damage that occurs from a heart attack), immune system disorders (e.g., inflammatory bowel disease, graft-versus-host disease) and neurological conditions (e.g., damage from an ischemic stroke).

Athersys has six clinical stage programs, including a pending Phase III study in ischemic stroke, an ongoing Phase II clinical study for the treatment of damage from acute myocardial infarction and an ongoing exploratory clinical study in acute respiratory distress syndrome.

Financial Highlights (FY 2023)

Company's Business Segments

• Regenerative Medicine : MultiStem Cell Therapy including Regenerative Medicine, advanced Therapy for the treatment of both Ischemic Stroke, Acute Respiratory Distress Syndrome.